Clinical trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract
19 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT06990659Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)University Hospital, Angers · PI: Christophe AUBE, Pr
- RECRUITINGPhase 2NCT07146646Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerCase Comprehensive Cancer Center · PI: Madison Conces, MD
- RECRUITINGPhase 2NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER · PI: Julien Edeline, MD
- RECRUITINGNCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCCHA University · PI: Hong Jae Chon, MD. PhD
- RECRUITINGNCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerCHA University · PI: Hong Jae Chon
- RECRUITINGPhase 2NCT07135544A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerYongjun Chen
- RECRUITINGNCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06708663HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd. · PI: Lin Shen
- RECRUITINGNCT06653127Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence SurveillanceTongji Hospital · PI: Ze-yang Ding, M.D.
- RECRUITINGPhase 2NCT06441747Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)Australasian Gastro-Intestinal Trials Group
- RECRUITINGPhase 2NCT04834674DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic CholangiocarcinomaSichuan Cancer Hospital and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06239194Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsModeX Therapeutics, An OPKO Health Company
- ACTIVE NOT RECRUITINGPhase 3NCT06109779Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)AstraZeneca
- ACTIVE NOT RECRUITINGPhase 3NCT05771480Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)AstraZeneca
- RECRUITINGPhase 3NCT07062263Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer PatientsTata Memorial Centre · PI: Vikas Ostwal, DM
- ACTIVE NOT RECRUITINGN/ANCT05921552Senior Adult Hepatobiliary Prehab StudyH. Lee Moffitt Cancer Center and Research Institute · PI: Mohammed Al-Jumayli, MD
- RECRUITINGPHASE2, PHASE3NCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerInnoPharmax Inc. · PI: Li-Tzong Chen, Ph.D
- ACTIVE NOT RECRUITINGPhase 1NCT04521686Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
- ACTIVE NOT RECRUITINGPhase 1NCT04459273Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersJonsson Comprehensive Cancer Center · PI: Jeremie Calais